{"id":5641,"date":"2023-12-04T09:15:33","date_gmt":"2023-12-04T09:15:33","guid":{"rendered":"https:\/\/aceoncology.org\/?post_type=ace_education&#038;p=5641"},"modified":"2023-12-18T12:30:35","modified_gmt":"2023-12-18T12:30:35","slug":"expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer","status":"publish","type":"ace_education","link":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/","title":{"rendered":"Expert Interview 4: Frequently Asked Questions (FAQs) for Second-Line (2L) and Salvage Treatments in Urothelial Cancer"},"content":{"rendered":"\n<p>There is a steadily widening range of second-line (2L) and subsequent treatment options for patients with advanced UC including chemotherapy, immune checkpoint inhibitors (ICIs) and novel therapies. In recent years, ICIs have predominantly replaced chemotherapy as the preferred 2L treatment. Furthermore, antibody-drug conjugates (ADC) and targeted agents have become available.<\/p>\n\n\n\n<div style=\"height:18px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>The selection of 2L and salvage treatments for advanced UC depends on many factors, including the initial treatment strategy used in the first-line setting. Molecular classifications appear to be promising in disease prognostication and prediction for UC.<\/p>\n\n\n\n<div style=\"height:17px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Let&#8217;s watch the recorded video on &#8216;Frequently Asked Questions (FAQs) for 2L and Salvage Treatments&#8217; to gain comprehensive insights from leading experts \u2013 Dr. Francisco X. Real from National Cancer Research Center of Spain and Dr. Enrique Grande from MD Anderson Cancer Center Madrid.<\/p>\n\n\n\n<div style=\"height:11px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>This program is available with subtitles in the following languages:<\/p>\n\n\n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/05\/Screenshot-2023-05-10-144115.png\" alt=\"This image has an empty alt attribute; its file name is Screenshot-2023-05-10-144115.png\"\/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>There is a steadily widening range of second-line (2L)  [&hellip;]<\/p>\n","protected":false},"author":719,"featured_media":5288,"template":"","ace_education_category":[35],"ace_education_tag":[],"class_list":["post-5641","ace_education","type-ace_education","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Expert Interview 4: Frequently Asked Questions (FAQs) for Second-Line (2L) and Salvage Treatments in Urothelial Cancer - ACE Oncology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Expert Interview 4: Frequently Asked Questions (FAQs) for Second-Line (2L) and Salvage Treatments in Urothelial Cancer - ACE Oncology\" \/>\n<meta property=\"og:description\" content=\"There is a steadily widening range of second-line (2L) [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"ACE Oncology\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-18T12:30:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"721\" \/>\n\t<meta property=\"og:image:height\" content=\"450\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:label1\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/\",\"url\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/\",\"name\":\"Expert Interview 4: Frequently Asked Questions (FAQs) for Second-Line (2L) and Salvage Treatments in Urothelial Cancer - ACE Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg\",\"datePublished\":\"2023-12-04T09:15:33+00:00\",\"dateModified\":\"2023-12-18T12:30:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/#primaryimage\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg\",\"width\":721,\"height\":450},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"ACE Oncology\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u5728\u7ebf\u6559\u80b2\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/education\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Expert Interview 4: Frequently Asked Questions (FAQs) for Second-Line (2L) and Salvage Treatments in Urothelial Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aceoncology.org\/#website\",\"url\":\"https:\/\/aceoncology.org\/\",\"name\":\"ACE Oncology\",\"description\":\"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.\",\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aceoncology.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aceoncology.org\/#organization\",\"name\":\"ACE Oncology\",\"url\":\"https:\/\/aceoncology.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"width\":156,\"height\":83,\"caption\":\"ACE Oncology\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ace_oncology\",\"https:\/\/www.linkedin.com\/company\/aceoncology\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Expert Interview 4: Frequently Asked Questions (FAQs) for Second-Line (2L) and Salvage Treatments in Urothelial Cancer - ACE Oncology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/","og_locale":"zh_CN","og_type":"article","og_title":"Expert Interview 4: Frequently Asked Questions (FAQs) for Second-Line (2L) and Salvage Treatments in Urothelial Cancer - ACE Oncology","og_description":"There is a steadily widening range of second-line (2L) [&hellip;]","og_url":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/","og_site_name":"ACE Oncology","article_modified_time":"2023-12-18T12:30:35+00:00","og_image":[{"width":721,"height":450,"url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@ace_oncology","twitter_misc":{"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/","url":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/","name":"Expert Interview 4: Frequently Asked Questions (FAQs) for Second-Line (2L) and Salvage Treatments in Urothelial Cancer - ACE Oncology","isPartOf":{"@id":"https:\/\/aceoncology.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/#primaryimage"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg","datePublished":"2023-12-04T09:15:33+00:00","dateModified":"2023-12-18T12:30:35+00:00","breadcrumb":{"@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/#primaryimage","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg","width":721,"height":450},{"@type":"BreadcrumbList","@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-4-frequently-asked-questions-faqs-for-second-line-2l-and-salvage-treatments-in-urothelial-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"ACE Oncology","item":"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/"},{"@type":"ListItem","position":2,"name":"\u5728\u7ebf\u6559\u80b2","item":"https:\/\/aceoncology.org\/zh-hans\/education\/"},{"@type":"ListItem","position":3,"name":"Expert Interview 4: Frequently Asked Questions (FAQs) for Second-Line (2L) and Salvage Treatments in Urothelial Cancer"}]},{"@type":"WebSite","@id":"https:\/\/aceoncology.org\/#website","url":"https:\/\/aceoncology.org\/","name":"ACE Oncology","description":"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.","publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aceoncology.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/aceoncology.org\/#organization","name":"ACE Oncology","url":"https:\/\/aceoncology.org\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","width":156,"height":83,"caption":"ACE Oncology"},"image":{"@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ace_oncology","https:\/\/www.linkedin.com\/company\/aceoncology"]}]}},"_links":{"self":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education\/5641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education"}],"about":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/types\/ace_education"}],"author":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/users\/719"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media\/5288"}],"wp:attachment":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media?parent=5641"}],"wp:term":[{"taxonomy":"ace_education_category","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education_category?post=5641"},{"taxonomy":"ace_education_tag","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education_tag?post=5641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}